BioSpace News Archive

Harrow Health, Inc., an ophthalmic‑focused healthcare company, announced that it will release its financial results for the fourth quarter and year ended December 31, 2021, on Thursday, March 10, 2022, after the market close.

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a collaboration and co-marketing partnership with Jumpcode Genomics that validates Jumpcode’s CRISPRclean technology on Element’s AVITI System.

Agilent Technologies Inc. and the University of Vermont announced the establishment of the Agilent Laboratory for Chemical Analysis.

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), today commented on Orphazyme A/S’s (NASDAQ: ORPH) (“Orphazyme”) announced update on the ongoing review of the Marketing Authorisation Application for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C (“NPC”) by the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”).

Stryker Launches PROstep™ MICA ® SOLO Guide to Simplify Minimally Invasive Bunion Procedures.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), today announced the U.S. commercial launch and availability of ELYXYBTM (celecoxib oral solution), the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine with or without aura in adults.

Evoke Pharma, Inc. announced that the results of a retrospective analysis of United States administrative claims data that examined the association between tardive dyskinesia and potential risk factors will be presented at the annual Digestive Disease Week Meeting in San Diego, CA taking place from May 21-24, 2022.

AmMax Bio, Inc. today announced that Michael Kavanaugh, M.D. has been appointed as an Independent Board Member.

A new study published on BioRxiv.org demonstrates that Vaxart’s S-only COVID-19 clinical vaccine candidate, now being studied by Vaxart in Phase II trials, generated antibodies to the original COVID-19 virus strain and to the beta, delta, alpha and gamma variants of SARS-CoV-2 in the serum and nasal mucosa of non-human primates (NHPs).

Valeo Pharma Inc., a Canadian pharmaceutical company, is proud to announce another major milestone for its two innovative Asthma therapies; Enerzair Breezehaler and Atectura Breezhaler, which have been accepted for reimbursement by the Ontario Drug Benefit program, the Manitoba Pharmacare Program, the New Brunswick Drug plan, and the NIHB and VAC federal programs.